PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Francesco Passiglia(University of Palermo), Antonio Russo(University of Palermo), Clara Natoli(Kliniken Essen-Mitte), Viviana Bazan(University of Palermo), Giuseppe Cicero(University of Palermo), Antonio Galvano(University of Palermo), Christian Rolfo(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Angela Listì(University of Palermo), Daniele Santini(Università Campus Bio-Medico), Sérgio Rizzo(University of Palermo), Giuseppe Bronte(University of Palermo)
Cited by 166
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642